SCHEMBL2861027

SCHEMBL2861027

CCCCCCCCCCCCCCCCCCCCCCO[C]=O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 8/20 0.43
CA2 P00918 8/20 0.43
CA9 Q16790 7/20 0.43
LPAR3 Q9UBY5 3/20 0.43
CA12 O43570 3/20 0.43
CA7 P43166 3/20 0.43
CA14 Q9ULX7 3/20 0.43
LPAR1 Q92633 2/20 0.43
LPAR2 Q9HBW0 2/20 0.43
CA3 P07451 2/20 0.43
CA4 P22748 2/20 0.43
CA6 P23280 2/20 0.43
CA5A P35218 2/20 0.43
CA5B Q9Y2D0 2/20 0.43
NAAA Q02083 1/20 0.43
TSHR P16473 2/20 0.42
THRB P10828 2/20 0.42
RECQL P46063 2/20 0.41
CES2 O00748 1/20 0.41
GLA P06280 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL55803 1.00 CA1 (0.43) CA1CA2CA9LPAR3CA12
SCHEMBL2855857 1.00 CA1 (0.43) CA1CA2CA9LPAR3CA12
SCHEMBL93201 1.00 CA1 (0.43) CA1CA2CA9LPAR3CA12
SCHEMBL2858733 1.00 CA1 (0.43) CA1CA2CA9LPAR3CA12
SCHEMBL2862726 1.00 CA1 (0.43) CA1CA2CA9LPAR3CA12
SCHEMBL68307 1.00 CA1 (0.43) CA1CA2CA9LPAR3CA12
SCHEMBL157306 1.00 CA1 (0.43) CA1CA2CA9LPAR3CA12
SCHEMBL2855746 1.00 CA1 (0.43) CA1CA2CA9LPAR3CA12
SCHEMBL77312 1.00 CA1 (0.43) CA1CA2CA9LPAR3CA12
SCHEMBL104986 1.00 CA1 (0.43) CA1CA2CA9LPAR3CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11179471-B2 Peptide for cytosolic delivery KYOTO UNIVERSITY (JP) 2021-11-23 US disclosed
WO-2021020462-A1 INTRACELLULAR DELIVERY PEPTIDE 国立大学法人京都大学 2021-02-04 WO disclosed
US-10730904-B2 Method for liquid-phase synthesis of nucleic acid TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2020-08-04 US disclosed
US-20200046840-A1 PEPTIDE FOR CYTOSOLIC DELIVERY KYOTO UNIVERSITY (JP) 2020-02-13 US disclosed
EP-3604520-A1 PEPTIDE FOR CYTOSOLIC DELIVERY Kyoto University (JP) 2020-02-05 EP disclosed
EP-2921499-B1 METHOD FOR LIQUID-PHASE SYNTHESIS OF NUCLEIC ACIDS TAKEDA PHARMACEUTICALS CO (JP) 2020-01-22 EP disclosed
CN-105924556-B Polymer comprising phthalocyanine structure, the method for preparing polymer, color compositions, pigment dispersion and toner 佳能株式会社 2019-08-30 CN disclosed
US-20190135852-A1 METHOD FOR LIQUID-PHASE SYNTHESIS OF NUCLEIC ACID TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2019-05-09 US disclosed
EP-3061775-B1 POLYMER INCLUDING PHTHALOCYANINE STRUCTURE, METHOD FOR PRODUCING THE POLYMER, PIGMENT COMPOSITION, PIGMENT DISPERSION, AND TONER CANON KK (JP) 2018-12-12 EP disclosed
US-9829814-B2 Toner CANON KABUSHIKI KAISHA (JP) 2017-11-28 US disclosed
US-5667959-A Silver halide photographic material and hydroxamic acid based compound used therefor FUJI PHOTO FILM CO., LTD. (JP) 1997-09-16 US disclosed
EP-0698814-A2 Silver halide photographic material with improved latent image stability FUJI PHOTO FILM CO., LTD. (JP) 1996-02-28 EP disclosed
US-4952470-A CONTAINING OZONE RESISTANCE ADDITIVE KONICA CORPORATION (JP) 1990-08-28 US disclosed
EP-0034950-B1 HETEROCYCLIC 4- AND 6-EQUIVALENT PHOTOGRAPHIC COLOUR COUPLERS AND PHOTOGRAPHIC MATERIALS AND DEVELOPER COMPOSITIONS CONTAINING THEM EASTMAN KODAK COMPANY (a New Jersey corporation) (US) 1986-01-08 EP disclosed
US-4410696-A Antitumor and immunosuppressive 4-carbamoylimidazolium-5-olate derivatives SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1983-10-18 US disclosed
EP-0075629-A1 Imidazole derivatives, their preparation, and their pharmaceutical compositions Sumitomo Chemical Industries Ltd. (JP) 1983-04-06 EP disclosed
US-4338393-A COLOR PHOTOGRAPHY EASTMAN KODAK COMPANY (US) 1982-07-06 US disclosed
US-4314011-A DISCOLORATION INHIBITORS KONISHIROKU PHOTO INDUSTRY CO., LTD. (JP) 1982-02-02 US disclosed
EP-0034950-A2 Heterocyclic 4- and 6-equivalent photographic colour couplers and photographic materials and developer compositions containing them EASTMAN KODAK COMPANY (a New Jersey corporation) (US) 1981-09-02 EP disclosed
US-4254216-A ANTIFADING ADDITIVE FOR FILMS KONISHIROKU PHOTO INDUSTRY CO., LTD. (JP) 1981-03-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190135852-A1 METHOD FOR LIQUID-PHASE SYNTHESIS OF NUCLEIC ACID RNGTT, POLR2H, POLR2E CA1 4486/4885CA2 4503/4885CA9 3880/4885
US-10730904-B2 Method for liquid-phase synthesis of nucleic acid RNGTT, POLR2H, POLR2E CA1 4503/4885CA2 4489/4885CA9 4189/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.